To reach the clinical stage and beyond
Translating research success into clinical benefit
EB is a rare and diverse group of conditions, with some subtypes classified as very rare. Nevertheless, rapid expansion of knowledge of EB over the past decade creates diverse opportunities for novel products, therapies, and diagnostics.
EB-ResNet has been established to coordinate research-active EB patient organisations and industry to bring effective, safe, life-changing treatments to EB patients. Four decades of research funding by EB-ResNet members and partners have created the disease knowledge base and clinical networks necessary to de-risk investment in clinical trials and market development.